Brief: Crossject Signs New Licensing Agreement On Zeneo® Midazolam Epilepsy Rescue Therapy With Aft Pharmaceuticals For Australia & New Zealand
20/07/2023 19:07
July 20 (Reuters) - Crossject SA 74C.F :
* CROSSJECT SIGNS NEW LICENSING AGREEMENT ON ZENEO®
MIDAZOLAM
EPILEPSY RESCUE THERAPY WITH AFT PHARMACEUTICALS FOR AUSTRALIA &
NEW ZEALAND
Source text for Eikon: ID:nGNX8n1rGh
Further company coverage: 74C.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure